ClinVar Miner

Submissions for variant NM_000051.4(ATM):c.8850+1G>A

dbSNP: rs1555143620
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 3
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Ambry Genetics RCV000568931 SCV000676329 likely pathogenic Hereditary cancer-predisposing syndrome 2017-05-22 criteria provided, single submitter clinical testing The c.8850+1G>A intronic variant results from a G to A substitution one nucleotide after coding exon 60 of the ATM gene. This nucleotide position is highly conserved in available vertebrate species. Using the BDGP and ESEfinder splice site prediction tools, this alteration is predicted to abolish the native splice donor site; however, direct evidence is unavailable. Alterations that disrupt the canonical splice site are expected to cause aberrant splicing, resulting in an abnormal protein or a transcript that is subject to nonsense-mediated mRNA decay. As such, this alteration is classified as likely pathogenic.
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV003492107 SCV004239979 pathogenic Breast and/or ovarian cancer 2022-09-02 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000568931 SCV004361931 likely pathogenic Hereditary cancer-predisposing syndrome 2023-03-29 criteria provided, single submitter clinical testing This variant causes a G to A nucleotide substitution at the +1 position of intron 61 of the ATM gene. Splice site prediction tools predict that this variant may have a significant impact on RNA splicing. Although this prediction has not been confirmed in published RNA studies, this variant is expected to result in an absent or disrupted protein product. This variant has been reported in an individual affected with pancreatic ductal adenocarcinomas (PMID: 30836094) and in an individual affected with breast cancer who also carried two co-variants in MLH1 gene and PALB2 gene (DOI: 10.1101/2022.05.31.22275080). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). Loss of ATM function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.